Month: July 2020

TORONTO, July 23, 2020 (GLOBE NEWSWIRE) — YAMANA GOLD INC. (TSX:YRI; NYSE:AUY) (“Yamana” or “the Company”) is herein reporting its financial and operational results for the second quarter of 2020. The Company posted strong quarterly production and free cash flow while further reducing net debt.    SECOND QUARTER HIGHLIGHTSStrong Adjusted Net Earnings and Cash Flows, Further Reduction in Net DebtAdjusted net earnings(1) of $63.3 million or $0.07 per share basic and diluted compared to adjusted net earnings of $19.8 million or $0.02 per share basic and diluted a year earlier.Net earnings were nil or nil per share basic and diluted compared to net earnings of $14.1 million or $0.01 per share basic and diluted a year earlier.(1)Strong quarterly cash flows from operating activities of $92.2 million and cash flow from operating activities...

MOUNTLAKE TERRACE, Wash., July 23, 2020 (GLOBE NEWSWIRE) — FS Bancorp, Inc. (NASDAQ:FSBW) (the “Company”), the holding company for 1st Security Bank of Washington (the “Bank”) today reported 2020 second quarter net income of $10.0 million, or $2.30 per diluted share, compared to $4.5 million, or $0.98 per diluted share for the same period last year.“During the last eight years of significant growth, we focused on maintaining diversified revenue streams through challenging economic environments.  The results of the second quarter reflect our diversified strategy and commitment to long-term shareholder value as we surpassed the $2 billion in assets mark this quarter,” stated Joe Adams, CEO.  “We are also pleased to announce that our Board of Directors has approved our thirtieth consecutive quarterly cash dividend. The quarterly dividend...

SUNNYVALE, Calif., July 23, 2020 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the second quarter 2020 after market close on Wednesday, August 5, 2020. Company management will host a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.Investors interested in listening to the conference call may do so by dialing (844) 883-3861 for domestic callers or (574) 990-9820 for international callers, using conference ID: 3681776. A live and archived webcast of the event will be available at https://investors.silkroadmed.com/.    About Silk Road MedicalSilk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is...

BOULDER, Colo., July 23, 2020 (GLOBE NEWSWIRE) — miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma. Cobomarsen is an inhibitor of miR-155 currently being developed by miRagen in two clinical programs to address different types of T-cell lymphoma, including a Phase 2 trial for cutaneous T-cell lymphoma (CTCL) and a Phase 1 trial for adult T-cell leukemia/lymphoma (ATLL).“This is an important milestone in the development of cobomarsen. We believe the FDA’s decision to grant cobomarsen orphan drug designation underscores the need for new treatments for T-cell lymphomas such as ATLL...

CORYDON, Ind., July 23, 2020 (GLOBE NEWSWIRE) — First Capital, Inc. (the “Company”) (NASDAQ:  FCAP), the holding company for First Harrison Bank (the “Bank”), today reported net income of $2.4 million or $0.73 per diluted share for the quarter ended June 30, 2020, compared to $2.9 million or $0.86 per diluted share for the quarter ended June 30, 2019.  The decrease was primarily due to a decrease in net interest income after provision for loan losses partially offset by an increase in noninterest income and a decrease in noninterest expense.Net interest income after provision for loan losses decreased $1.3 million for the quarter ended June 30, 2020 as compared to the same period in 2019.  Interest income decreased $845,000 when comparing the periods due to a decrease in the average tax-equivalent yield on interest-earning assets...

Malta, 23 July 2020Kambi Group plc and DraftKings Inc. Reach Agreement on DraftKings’ Migration PhaseTwo companies to mutually support and cooperate on DraftKings’ migration to proprietary technology, DraftKings to take additional steps to safeguard Kambi’s intellectual propertyKambi Group plc and DraftKings Inc. have reached a mutual agreement regarding the migration phase of DraftKings to its proprietary technology from the Kambi sportsbook platform, which secures Kambi with full revenue until the end of the partnership and increases the protections for its intellectual property.The agreement governing the provision of Kambi’s world-leading sports betting technology and services to DraftKings will end no earlier than 30 September 2021, however, DraftKings is permitted to leverage its proprietary technology, in full or part, prior to...

NEWARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) — ShotSpotter, Inc. (Nasdaq: SSTI), the leader in solutions that help law enforcement officials identify, locate and deter gun violence, today announced that the ranger service of the Kruger National Park in South Africa has successfully driven a nearly 60% reduction in the number of rhino killed within ShotSpotter’s coverage area inside the iconic park’s Intensified Protection Zone (IPZ).Since November 2018, ShotSpotter has been incrementally deployed across several areas of the IPZ. These areas were specifically chosen due to the high density of rhinos living within the coverage areas and the strategic importance of these animals to the overall rhino gene pool. During the 12 months prior to ShotSpotter’s deployment, officials at Kruger National Park reported that 12 rhinos were killed...

HOUSTON, July 23, 2020 (GLOBE NEWSWIRE) — News Release – TC PipeLines, LP (NYSE: TCP) (the Partnership) today announced that the board of directors of TC PipeLines GP, Inc., its general partner, declared the Partnership’s second quarter 2020 cash distribution of $0.65 per common unit. The distribution is unchanged from the distribution declared for the first quarter of 2020.This cash distribution is the 85th consecutive quarterly distribution paid by the Partnership and is payable on August 14, 2020 to unitholders of record at the close of business on August 3, 2020.About TC PipeLines, LPTC PipeLines, LP is a Delaware master limited partnership with interests in eight federally regulated U.S. interstate natural gas pipelines which serve markets in the Western, Midwestern and Northeastern United States. The Partnership is managed...

SummaryNet income of $12.6 million, or $0.53 diluted earnings per shareTotal loans increased $463.2 million, or 10.6%, from the end of the prior quarterTotal deposits increased $292.5 million, or 6.3%, from the end of the prior quarterEfficiency ratio of 58.5%Allowance for credit losses strengthened to 0.97% of total loans$276.0 million in Paycheck Protection Program loans as of June 30, 2020EFFINGHAM, Ill., July 23, 2020 (GLOBE NEWSWIRE) — Midland States Bancorp, Inc. (Nasdaq: MSBI) (the “Company”) today reported net income of $12.6 million, or $0.53 diluted earnings per share, for the second quarter of 2020.  This compares to net income of $1.5 million, or $0.06 diluted earnings per share, for the first quarter of 2020, which was impacted by an $8.5 million impairment on commercial mortgage servicing rights (“MSR”) and $1.0 million...

Menarini licenses global development and commercialization rights of elacestrant, an oral SERD currently in late stage Phase 3 developmentElacestrant further strengthens Menarini’s global oncology portfolio, recently bolstered by the acquisition of Stemline Therapeutics in the U.S.Radius will receive $30M as an upfront payment and up to $320M in additional milestones along with tiered low to mid-teen percentage royaltiesWALTHAM, Mass. and FLORENCE, Italy, July 23, 2020 (GLOBE NEWSWIRE) — The Menarini Group and Radius Health, Inc. (Nasdaq: RDUS) announced today that the companies have entered into an exclusive global license agreement for development and commercialization of elacestrant.  Elacestrant is an oral SERD, a selective estrogen receptor degrader, currently being evaluated in the EMERALD Phase 3 study as hormonal treatment...